Literature DB >> 30047422

Germline GATA2 Mutation and Bone Marrow Failure.

Lisa J McReynolds1, Katherine R Calvo2, Steven M Holland3.   

Abstract

GATA2 deficiency is an immunodeficiency and bone marrow failure disorder caused by pathogenic variants in GATA2. It is inherited in an autosomal-dominant pattern or can be due to de novo sporadic germline mutation. Patients commonly have B-cell, dendritic cell, natural killer cell, and monocytopenias, and are predisposed to myelodysplastic syndrome, acute myeloid leukemia, and chronic myelomonocytic leukemia. Patients may suffer from disseminated human papilloma virus and mycobacterial infections, pulmonary alveolar proteinosis, and lymphedema. The bone marrow eventually takes on a characteristic hypocellular myelodysplasia with loss of monocytes and hematogones, megakaryocytes with separated nuclear lobes, micromegakaryocytes, and megakaryocytes with hypolobated nuclei. Published by Elsevier Inc.

Entities:  

Keywords:  GATA2; MDS; Micromegakaryocytes; Monocytopenia

Mesh:

Substances:

Year:  2018        PMID: 30047422      PMCID: PMC6128284          DOI: 10.1016/j.hoc.2018.04.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  79 in total

1.  GATA2 mutations lead to MDS and AML.

Authors:  R Katherine Hyde; P Paul Liu
Journal:  Nat Genet       Date:  2011-09-28       Impact factor: 38.330

2.  Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.

Authors:  Jennifer Cuellar-Rodriguez; Juan Gea-Banacloche; Alexandra F Freeman; Amy P Hsu; Christa S Zerbe; Katherine R Calvo; Jennifer Wilder; Roger Kurlander; Kenneth N Olivier; Steven M Holland; Dennis D Hickstein
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

3.  Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease.

Authors:  Markus Maeurer; Isabelle Magalhaes; Jan Andersson; Per Ljungman; Erik Sandholm; Michael Uhlin; Jonas Mattsson; Olle Ringdén
Journal:  Transplantation       Date:  2014-12-27       Impact factor: 4.939

4.  Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis.

Authors:  Stéphane Jouneau; Alice Ballerie; Mallorie Kerjouan; Xavier Demant; Elodie Blanchard; Mathieu Lederlin
Journal:  Eur Respir J       Date:  2017-05-11       Impact factor: 16.671

5.  Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency.

Authors:  Alice Ballerie; Stanislas Nimubona; Catherine Meunier; Francisco Llamas Gutierrez; Benoît Desrues; Philippe Delaval; Stéphane Jouneau
Journal:  Eur Respir J       Date:  2016-10-20       Impact factor: 16.671

6.  Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency.

Authors:  Kevin E Fisher; Amy P Hsu; Christopher L Williams; Hadi Sayeed; Brian Y Merritt; M Tarek Elghetany; Steven M Holland; Alison A Bertuch; Maria Monica Gramatges
Journal:  Blood Adv       Date:  2017-02-27

7.  Pediatric MDS: GATA screen the germline.

Authors:  Elliot Stieglitz; Mignon L Loh
Journal:  Blood       Date:  2016-03-17       Impact factor: 22.113

8.  GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome.

Authors:  Amy P Hsu; Kirby D Johnson; E Liana Falcone; Rajendran Sanalkumar; Lauren Sanchez; Dennis D Hickstein; Jennifer Cuellar-Rodriguez; Jacob E Lemieux; Christa S Zerbe; Emery H Bresnick; Steven M Holland
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113

9.  Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset.

Authors:  Emily M Mace; Amy P Hsu; Linda Monaco-Shawver; George Makedonas; Joshua B Rosen; Lesia Dropulic; Jeffrey I Cohen; Eugene P Frenkel; John C Bagwell; John L Sullivan; Christine A Biron; Christine Spalding; Christa S Zerbe; Gulbu Uzel; Steven M Holland; Jordan S Orange
Journal:  Blood       Date:  2013-01-30       Impact factor: 22.113

10.  Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes.

Authors:  C-E Chong; P Venugopal; P H Stokes; Y K Lee; P J Brautigan; D T O Yeung; M Babic; G A Engler; S W Lane; M Klingler-Hoffmann; J M Matthews; R J D'Andrea; A L Brown; C N Hahn; H S Scott
Journal:  Leukemia       Date:  2017-06-23       Impact factor: 11.528

View more
  20 in total

Review 1.  Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.

Authors:  Emery H Bresnick; Kirby D Johnson
Journal:  Blood Adv       Date:  2019-07-09

Review 2.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

Review 3.  The clinical and laboratory evaluation of patients with suspected hypocellular marrow failure.

Authors:  Siobán Keel; Amy Geddis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  Distinguishing constitutional from acquired bone marrow failure in the hematology clinic.

Authors:  Emma M Groarke; Neal S Young; Katherine R Calvo
Journal:  Best Pract Res Clin Haematol       Date:  2021-06-02       Impact factor: 3.670

Review 5.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

6.  Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes.

Authors:  Joseph H Oved; Daria V Babushok; Michele P Lambert; Nicole Wolfset; M Anna Kowalska; Mortimer Poncz; Konrad J Karczewski; Timothy S Olson
Journal:  Blood Adv       Date:  2020-10-27

7.  A patient with a germline GATA2 mutation and primary myelofibrosis.

Authors:  Cyrill V Rütsche; Eugenia Haralambieva; Veronika Lysenko; Stefan Balabanov; Alexandre P A Theocharides
Journal:  Blood Adv       Date:  2021-02-09

8.  Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.

Authors:  John C Molina; Julie M Asare; Laura Tuschong; Robert R West; Katherine R Calvo; Rebecca Persky; Alison M Boyce; Dima A Hammoud; Steven M Holland; Dennis Hickstein; Nirali N Shah
Journal:  Pediatr Blood Cancer       Date:  2020-12-27       Impact factor: 3.838

Review 9.  Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?

Authors:  Emery H Bresnick; Mabel M Jung; Koichi R Katsumura
Journal:  Blood Adv       Date:  2020-09-22

10.  Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages.

Authors:  Serine Avagyan; Margaret C Weber; Sai Ma; Meera Prasad; William P Mannherz; Song Yang; Jason D Buenrostro; Leonard I Zon
Journal:  Blood Adv       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.